Evidence map›Paper›PMID 37824386›Full record

ArticleCritical reviews in oncogenesis2023

Fifty Years of Diazeniumdiolate Research: A Tribute to Dr. Larry K. Keefer.

Khosrow Kashfi

Abstract read
In one paragraph

Article in Critical reviews in oncogenesis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Khosrow KashfiDepartment of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, 160 Convent Avenue, New York, NY 10031, USA; Graduate Program in Biology, City University of New York Graduate Center, New York, NY, USA.

Funding

Delivery of H2S: Supramolecular and Enzyme-Triggered Strategies for Controlled ReleaseR01GM123508 · NIGMS · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI MATSON, JOHN B · 2017 to 2021
$1.6M
NIGMS NIH HHS R01 GM123508
6 · The paper itself

Abstract

The pioneering studies of Dr. Larry Keefer and colleagues with diazeniumdiolates or NONOates as a platform have unraveled the chemical biology of many nitric oxides and have led to the design of a variety of promising therapeutic agents in oncology, gastroenterology, antimicrobials, wound healing, and the like. This dedication to Dr. Larry Keefer briefly highlights some of his studies using the diazeniumdiolate platform in the cancer arena.

Indexed as

NeoplasmsNitric OxideAzo CompoundsHumansNitric Oxide DonorsAzo CompoundsdiazeniumdiolateNitric OxideNitric Oxide Donors

Identifiers

PMID37824386
PMCPMC11076142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.